Skip to Content

New Drug Approvals Archive - February 2016

February 2016

Sernivo (betamethasone dipropionate) Topical Spray

Date of Approval: February 5, 2016
Company: Promius Pharma, LLC
Treatment for: Plaque Psoriasis

Sernivo Spray (betamethasone dipropionate) is a topical corticosteroid indicated for the treatment of mild to moderate plaque psoriasis.

Read more: Sernivo (betamethasone dipropionate) FDA Approval History

Briviact (brivaracetam) Tablets, Solution and Injection

Date of Approval: February 19, 2016
Company: UCB, Inc.
Treatment for: Epilepsy

Briviact (brivaracetam) is a selective, high-affinity synaptic vesicle protein 2A ligand and analog of levetiracetam indicated for the treatment of partial-onset seizures in patients with epilepsy.

Read more: Briviact (brivaracetam) FDA Approval History

New Drug Approvals Archive